Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZIOP

ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis

ZIOPHARM Oncology logo

About ZIOPHARM Oncology Stock (NASDAQ:ZIOP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.82
$1.39
52-Week Range
N/A
Volume
2.13 million shs
Average Volume
2.01 million shs
Market Capitalization
$187.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZIOP Stock News Headlines

Best Global Universities for Oncology
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
Alx Oncology Holdings (ALXO)
CG Oncology Inc
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
WBSPH 2024 - Oncology
See More Headlines

ZIOP Stock Analysis - Frequently Asked Questions

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $0.40 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIOPHARM Oncology investors own include Precigen (PGEN), Bristol Myers Squibb (BMY), OPKO Health (OPK), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN) and CorMedix (CRMD).

Company Calendar

Last Earnings
11/08/2021
Today
9/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZIOP
CIK
1107421
Employees
105
Year Founded
2005

Profitability

EPS (Trailing Twelve Months)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$79.98 million
Net Margins
N/A
Pretax Margin
-22,544.97%
Return on Equity
-92.84%
Return on Assets
-72.46%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
3.43
Quick Ratio
3.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
216,146,000
Free Float
204,906,000
Market Cap
$187.12 million
Optionable
Optionable
Beta
1.71

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ZIOP) was last updated on 9/7/2025 by MarketBeat.com Staff
From Our Partners